JANXJanux Therapeutics, Inc.
$18.51-18% 1Y
$18.51
$12.1852 weeks$34.74
The financials
Janux Therapeutics, Inc. by the numbers
Janux Therapeutics, Inc. (JANX) reported revenue of $10M in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $22M. For the full year FY2025, revenue was $10M (−5.6% year on year) and net income −$114M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $10M | $0 | n/a |
| Operating income | −$32M | −$45M | n/a |
| Net income | −$22M | −$34M | n/a |
| Diluted EPS | −$0.35 | −$0.55 | n/a |